In vivo demonstration of amyloid burden in posterior cortical atrophy: A case series with PET and CSF findings

Journal of Neurology

Volumn 258, Issue 10, 2011, Pages 1841-1851

  Formaglio, Maïté ^a,c   Costes, Nicolas ^b,c   Seguin, Jérémie ^a,c   Tholance, Yannick ^a,c   Le Bars, Didier ^b,c   Roullet Solignac, Isabelle ^a   Mercier, Bernadette ^a   Krolak Salmon, Pierre ^a,c,d   Vighetto, Alain ^a,c,e  

^a HOSPICES CIVILS DE LYON   (France)

^b CERMEP IMAGERIE DU VIVANT   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE HOSPITALIER LE VINATIER   (France)

^e INSERM   (France)

Author keywords

Alzheimer's disease; CSF biomarkers; PET; Pittsburgh Compound B; Posterior cortical atrophy; Voxel based analysis

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; TAU PROTEIN; THREONINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN MAPPING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG UPTAKE; EDUCATIONAL STATUS; FEMALE; HUMAN; IN VIVO STUDY; MALE; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CORTICAL ATROPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; BRAIN; FEMALE; HUMANS; MALE; NEURODEGENERATIVE DISEASES; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 80054718827     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6030-0     Document Type: Article

References (56)

1. DF Benson RJ Davis BD Snyder 1988 Posterior cortical atrophy Arch Neurol 45 7 789 793 3390033 1:STN:280:DyaL1c3mvVCrsQ%3D%3D
2. DF Tang-Wai, et al. 2004 Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy Neurology 63 7 1168 1174 15477533 1:STN:280:DC%2BD2crgvVWhug%3D%3D (Pubitemid 39350012)
3. JA Renner, et al. 2004 Progressive posterior cortical dysfunction: a clinicopathologic series Neurology 63 7 1175 1180 15477534 1:STN:280: DC%2BD2crhtFegtw%3D%3D (Pubitemid 39350013)
4. P McMonagle, et al. 2006 The cognitive profile of posterior cortical atrophy Neurology 66 3 331 338 16476930 10.1212/01.wnl.0000196477.78548.db (Pubitemid 43739932)
5. Formaglio M et al (2009) Homonymous hemianopia and posterior cortical atrophy. Rev Neurol (Paris) 165(3):256-62
6. JL Whitwell, et al. 2007 Imaging correlates of posterior cortical atrophy Neurobiol Aging 28 7 1051 1061 16797786 10.1016/j.neurobiolaging.2006.05.026 (Pubitemid 46635917)
7. PJ Nestor, et al. 2003 The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET J Neurol Neurosurg Psychiatry 74 11 1521 1529 14617709 10.1136/jnnp.74.11.1521 1:STN:280:DC%2BD3srksVKiug%3D%3D (Pubitemid 37392875)
8. K Schmidtke M Hull J Talazko 2005 Posterior cortical atrophy: variant of Alzheimer's disease? A case series with PET findings J Neurol 252 1 27 35 15654552 10.1007/s00415-005-0594-5 (Pubitemid 40179015)
9. S Alladi, et al. 2007 Focal cortical presentations of Alzheimer's disease Brain 130 Pt 10 2636 2645 17898010 10.1093/brain/awm213 1:STN:280: DC%2BD2srns1Ggug%3D%3D (Pubitemid 47511719)
10. PR Hof, et al. 1997 Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways Vision Res 37 24 3609 3625 9425534 10.1016/S0042-6989(96)00240-4 1:STN:280:DyaK1c%2Fos1Kksw%3D%3D (Pubitemid 27491638)
11. F Hulstaert, et al. 1999 Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF Neurology 52 8 1555 1562 10331678 1:STN:280:DyaK1M3mtVGhsw%3D%3D (Pubitemid 29220627)
12. LM Shaw, et al. 2009 Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 4 403 413 19296504 10.1002/ana.21610 1:CAS:528:DC%2BD1MXmtVylsLY%3D
13. CA Mathis, et al. 2002 A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain Bioorg Med Chem Lett 12 3 295 298 11814781 10.1016/S0960-894X(01)00734-X 1:CAS:528:DC%2BD38XpslKmtQ%3D%3D (Pubitemid 34113887)
14. WE Klunk, et al. 2004 Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 3 306 319 14991808 10.1002/ana.20009 1:CAS:528:DC%2BD2cXisFKntb8%3D (Pubitemid 38269583)
15. H Engler, et al. 2006 Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 Pt 11 2856 2866 16854944 10.1093/brain/awl178 (Pubitemid 44684508)
16. BJ Bacskai, et al. 2007 Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report Arch Neurol 64 3 431 434 17353389 10.1001/archneur.64.3.431 (Pubitemid 46425701)
17. A Lockhart, et al. 2007 PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis Brain 130 Pt 10 2607 2615 17698496 10.1093/brain/awm191 1:STN:280:DC%2BD2srnsV2mug%3D%3D (Pubitemid 47511709)
18. MD Ikonomovic, et al. 2008 Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 Pt 6 1630 1645 18339640 10.1093/brain/awn016 (Pubitemid 351806448)
19. MF Folstein FS Folstein PR McHugh 1975 Mini-mental state. A pratical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189 198 1202204 10.1016/0022-3956(75)90026-6 1:STN:280: DyaE28%2FntFKjtw%3D%3D
20. JC Morris 1993 The clinical dementia rating (CDR): current version and scoring rules Neurology 43 11 2412 2414 8232972 1:STN:280:DyaK2c%2FltVKnuw%3D%3D (Pubitemid 23346995)
21. G McKhann, et al. 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 7 939 944 6610841 1:STN:280:DyaL2c3ks1altQ%3D%3D (Pubitemid 14076461)
22. E Grober H Buschke 1987 Genuine memory deficits in dementia Dev Psychol 3 13 36
23. Delis D et al (1987) The California Verbal Learning Test (research Ždition). Psychological corporation, New York
24. DDB Cardebat M Puel P Goulet Y Joanette 1990 Formal and semantic lexial evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level Acta Neurol Belg 90 207 217 2124031 1:STN:280:DyaK3M%2FnsF2qug%3D%3D
25. Bachy-Langedock N (1989) Batterie d'examen des troubles en denomination, Editest, Bruxelles
26. Stroop 1935 Studies of interferences in serial verbal reactions J Exp Psychol 18 643 662 10.1037/h0054651
27. RM Reitan D Wolfson 2004 The Trail Making Test as an initial screening procedure for neuropsychological impairment in older children Arch Clin Neuropsychol 19 2 281 288 15010091 10.1016/S0887-6177(03)00042-8 (Pubitemid 38316876)
28. LJ Rapport SR Millis PJ Bonello 1998 Validation of the Warrington theory of visual processing and the visual object and space perception battery J Clin Exp Neuropsychol 20 2 211 220 9777475 10.1076/jcen.20.2.211.1169 1:STN:280:DyaK1cvltVKmsg%3D%3D (Pubitemid 28451700)
29. T Sunderland, et al. 1989 Clock drawing in Alzheimer's disease. A novel measure of dementia severity J Am Geriatr Soc 37 8 725 729 2754157 1:STN:280:DyaL1MzislOrsQ%3D%3D (Pubitemid 19199790)
30. O Hansson, et al. 2006 Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 3 228 234 16488378 10.1016/S1474-4422(06)70355-6 1:CAS:528:DC%2BD28XisF2qsbg%3D (Pubitemid 43238346)
31. T Tapiola, et al. 2009 Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 3 382 389 19273758 10.1001/archneurol.2008.596
32. N Mattsson, et al. 2009 CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment Jama 302 4 385 393 19622817 10.1001/jama.2009.1064 1:CAS:528:DC%2BD1MXptVCgu7Y%3D
33. BJ Lopresti, et al. 2005 Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis J Nucl Med 46 12 1959 1972 16330558 1:CAS:528:DC%2BD28XivVSktQ%3D%3D (Pubitemid 46657441)
34. A Hammers, et al. 2003 Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe Hum Brain Mapp 19 4 224 247 12874777 10.1002/hbm.10123 (Pubitemid 36959351)
35. J Ashburner KJ Friston 2005 Unified segmentation Neuroimage 26 3 839 851 15955494 10.1016/j.neuroimage.2005.02.018 (Pubitemid 40825026)
36. Kambe T et al (2010) Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex. J Neurol 257(3):469-71
37. R Migliaccio, et al. 2009 Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum Neurology 73 19 1571 1578 19901249 10.1212/WNL.0b013e3181c0d427 1:STN:280:DC%2BD1MjkvFOiuw%3D%3D
38. O Tenovuo, et al. 2008 Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation J Alzheimers Dis 15 3 351 355 18997288 1:CAS:528:DC%2BD1cXhtlaisLrM
39. SY Ng, et al. 2007 Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B Arch Neurol 64 8 1140 1144 17698704 10.1001/archneur.64.8.1140 (Pubitemid 47258073)
40. T Grimmer, et al. 2009 Clinical severity of Alzheimer's disease is associated with PIB uptake in PET Neurobiol Aging 30 12 1902 1909 18346821 10.1016/j.neurobiolaging.2008.01.016 1:CAS:528:DC%2BD1MXht1yjtb%2FP
41. P Edison, et al. 2007 Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study Neurology 68 7 501 508 17065593 10.1212/01.wnl.0000244749.20056.d4 1:STN:280:DC%2BD2s%2FpsFymsA%3D%3D
42. NM Kemppainen, et al. 2007 PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment Neurology 68 19 1603 1606 17485647 10.1212/01.wnl.0000260969.94695.56 1:CAS:528:DC%2BD2sXkvVWks70%3D (Pubitemid 46717985)
43. Rabinovici GD et al (2010) Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 133(Pt 2): p 512-28
44. A Forsberg, et al. 2008 PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 10 1456 1465 17499392 10.1016/j.neurobiolaging.2007.03.029 1:CAS:528:DC%2BD1cXhtVSjsr%2FI
45. SN Gomperts, et al. 2008 Imaging amyloid deposition in Lewy body diseases Neurology 71 12 903 910 18794492 10.1212/01.wnl.0000326146.60732.d6 1:STN:280:DC%2BD1cngs1amtw%3D%3D
46. P Edison, et al. 2008 Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography J Neurol Neurosurg Psychiatry 79 12 1331 1338 18653550 10.1136/jnnp.2007.127878 1:STN:280:DC%2BD1cjktFSgsg%3D%3D
47. KE Pike, et al. 2007 Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain 130 Pt 11 2837 2844 17928318 10.1093/brain/awm238 (Pubitemid 350033975)
48. VL Villemagne, et al. 2008 Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease Neuropsychologia 46 6 1688 1697 18343463 10.1016/j.neuropsychologia. 2008.02.008 1:STN:280:DC%2BD1cvivVKmtQ%3D%3D
49. Baumann TP et al (2010) CSF-Tau and CSF-Abeta(1-42) in posterior cortical atrophy. Dement Geriatr Cogn Disord 29(6):530-533
50. D Strozyk, et al. 2003 CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 4 652 656 12601108 1:STN:280:DC%2BD3s%2FovF2gtw%3D%3D (Pubitemid 36246085)
51. AE Roher, et al. 2009 Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease Biomarkers 14 7 493 501 19863188 10.3109/13547500903108423 1:CAS:528:DC%2BD1MXhtleitb3K
52. K Koopman, et al. 2009 Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P) Neurochem Int 55 4 214 218 19524111 10.1016/j.neuint.2009.02.017 1:CAS:528: DC%2BD1MXnt1Gjtb4%3D
53. Mulder C et al (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56(2):248-53
54. Hort J et al (2010) Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 17(1):90-6
55. S Engelborghs, et al. 2008 Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia Neurobiol Aging 29 8 1143 1159 17428581 10.1016/j.neurobiolaging.2007.02.016 (Pubitemid 351822410)
56. K Iqbal, et al. 2005 Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers Ann Neurol 58 5 748 757 16247771 10.1002/ana.20639 1:CAS:528:DC%2BD2MXht1Cgu7rN (Pubitemid 41552550)